CureVac NV CVAC.OQ, CVAC.O is expected to show a rise in quarterly revenue when it reports results on August 13 (estimated) for the period ending June 30 2025
The Tuebingen Baden-wuerttemberg-based company is expected to report a 139.6% increase in revenue to €34.588 million from €14.44 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for CureVac NV is for a loss of 18 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for CureVac NV is $5.46, about 0.4% above its last closing price of $5.44
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.20 | -0.19 | -0.23 | Missed | -21.1 |
Dec. 31 2025 | -0.21 | -0.14 | Beat | 34.1 | |
Sep. 30 2024 | -0.08 | 0.56 | 1.50 | Beat | 166.7 |
Jun. 30 2024 | -0.31 | -0.26 | -0.32 | Missed | -20.8 |
Mar. 31 2024 | -0.24 | -0.23 | -0.31 | Missed | -36 |
Dec. 31 2023 | -0.18 | -0.39 | Missed | -110.8 | |
Sep. 30 2023 | -0.18 | -0.23 | -0.22 | Beat | 3.5 |
Jun. 30 2023 | -0.24 | -0.24 | -0.30 | Missed | -25 |
This summary was machine generated August 11 at 13:13 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)